Kinaset Therapeutics
Kinaset Therapeutics is focused on developing inhaled therapeutics for respiratory diseases, with a particular emphasis on a non-invasive anti-inflammatory approach. They are advancing towards clinical trials with their lead candidate KN-002, aimed at treating severe asthma regardless of the inflammation cause. The company aims to deliver drugs directly to the lungs while minimizing systemic exposure, and is actively involved in clinical evaluations and partnerships.
Industries
Nr. of Employees
small (1-50)
Kinaset Therapeutics
Boston, Massachusetts, United States, North America
Products
Clinical-stage inhaled anti-inflammatory therapeutic candidate (inhalation delivery)
A clinical-stage inhaled anti-inflammatory candidate developed for treatment of severe asthma and other respiratory inflammatory conditions; designed for direct pulmonary delivery to reduce systemic exposure and assessed in Phase 1/1b studies.
frevecitinib
An inhaled therapeutic candidate being developed by Kinaset Therapeutics to address significant unmet medical needs in respiratory diseases.
frevecitinib (KN-002)
A novel, non-invasive inhaled pan-JAK inhibitor formulated as a dry powder designed to target the site of inflammation in the lungs for the treatment of severe asthma regardless of underlying inflammation type.
Clinical-stage inhaled anti-inflammatory therapeutic candidate (inhalation delivery)
A clinical-stage inhaled anti-inflammatory candidate developed for treatment of severe asthma and other respiratory inflammatory conditions; designed for direct pulmonary delivery to reduce systemic exposure and assessed in Phase 1/1b studies.
frevecitinib
An inhaled therapeutic candidate being developed by Kinaset Therapeutics to address significant unmet medical needs in respiratory diseases.
frevecitinib (KN-002)
A novel, non-invasive inhaled pan-JAK inhibitor formulated as a dry powder designed to target the site of inflammation in the lungs for the treatment of severe asthma regardless of underlying inflammation type.
Services
Engaging external partners for collaboration, licensing, or co-development of respiratory therapeutic programs.
Engaging external partners for collaboration, licensing, or co-development of respiratory therapeutic programs.
Expertise Areas
- Inhaled therapeutics for respiratory disease
- Early-phase clinical trial management (Phase I/IB)
- Pulmonary drug formulation and delivery
- Regulatory strategy and IND submissions
Key Technologies
- Inhalation drug delivery
- Pulmonary-targeted formulation
- Early-phase clinical trial design
- IND regulatory submission processes